Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease.

This publication has 30 references indexed in Scilit:

• Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study
  Gastroenterology, 2003
• CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD)
  Gastroenterology, 2003
• CDP571, a humanized monoclonal antibody to TNF-α, a well tolerated alternative in Crohn's disease patients who have experienced hypersensitivity reactions to infliximab
  Gastroenterology, 2003
• Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open‐label, pilot study
  Alimentary Pharmacology & Therapeutics, 2003
• Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
  Arthritis & Rheumatism, 2002
• Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
  Arthritis & Rheumatism, 2002
• Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
  Published by Elsevier ,2002
• Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
  New England Journal of Medicine, 2001
• A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human anti body to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease
  Gastroenterology, 2000
• Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
  New England Journal of Medicine, 1999